Resmetirom has reduced the MRI-PDFF significantly in patients with biopsy-confirmed NASH along with other related parameters (LDL, Apo-B, TGs) supporting efficacy and safety of resmetirom. The gene discussed is APOB; the disease is metabolic dysfunction-associated steatohepatitis.